摘要
组织型纤溶酶原激活剂(tPA)和纤溶酶原激活物抑制剂-1(PAI-1)是纤溶系统的主要调控因子。2型糖尿病患者高血糖、高胰岛素血症、脂代谢紊乱、炎症反应、肥胖等多种因素可引起血浆tPA水平降低、PAI-1水平升高。纤溶活性的降低参与了大血管病变的发生、发展。提高纤溶活性的综合治疗将对防治糖尿病大血管并发症起一定作用。
出处
《国外医学(内分泌学分册)》
2005年第B04期42-44,共3页
Foreign Medical Sciences(Section of Endocrinology)
参考文献18
-
1Leurs PB, Stolk RP, Hamulyak K, et al. Tissue factor pathway inhibitor and endothelium-dependent hemostatic factors in elderly individuls with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care,2002,25:1340-1345.
-
2Lapolla A, Piarulli F, Sartore G, et al. Peripheral artery disease in type 2diabetes: the role of fibrinolysis. Thromb Haemost, 2003,89: 91-96.
-
3Lee HS, Moon KC, Song CY, et al. Glycated albumin activates PAI-1transcription through Smad DNA binding sites in mesangial cells. Am J Physiol Renal Physiol, 2004,287: 665-672.
-
4Pandolfi A, Giaccari A, Cilli C, et al. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrionlytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol, 2001,38:71-76.
-
5Suzuki M, Akimoto K, Hattori Y. Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells. Life Sci, 2002,72: 59-66.
-
6Samad F, Pandey M, Bell PA, et al. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol Med,2000,6: 680-692.
-
7Banfi C, Eriksson P, Giandomenico G, et al. Transcriptional regulation of plasminngen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. Diabetes,2001,50:1522-1530.
-
8Nordt TK, Bode C, Sobel BE. Stimulation in vivo of expression of intraabdominal adipose tissue plasminogen activator inhibitor type 1 by proinsulin. Diabetologia,2001,44:1121-1124.
-
9Krebs M, Geiger M, Polak K, et al. Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man. Thromb Haemost, 2003,90: 422-428.
-
10Zhang J, Ren S, Shen GX. Glycation amplifies lipoprotein( a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis,2000,150:299-308.
同被引文献18
-
1陶少平.糖尿病肾病的早期诊治进展[J].中华全科医学,2003,5(1):61-63. 被引量:11
-
2吴国仲,吴永贵.糖尿病肾病发病炎症机制研究进展[J].国外医学(泌尿系统分册),2005,25(3):363-367. 被引量:46
-
3Koji Y,Kyosuke T,Tetsuhito K,et al.Aging and plasminogen activatorinhibitor-1(PAI-1)regulation:implication in the pathogenesis of throm-botic disorders in the elderly.Cardiovascular Research,2005,66(3):226-285.
-
4Navarro JF,Mora C,Gomez M,et al.Influence of renal involvemention peripheral blood mononuclear cell expression bchaviour of tumour necrosis factor-alpha and interlcukin -6 in type 2 diabetic patients.Nephrol Dial Tmnsplant,2008,23(3):919-926.
-
5Galajda P,Martinda E,Mokan M,et al.Endothelial markers in diabetes Mellitus[J].Thromb Res,1997,85:63~65.
-
6Estelles A,Tormo G,Aznar J,et al.Reduced fibrinolytie octivity in cornary heart disease in dasal condition and ajter exercise[J].Thomb Res,1985,40:373~378.
-
7Cardona F, Tinahones FJ, collantes E, et al. The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates[ J]. Rheum, 2003, 42 : 468-472.
-
8Estelles A, Tormo G, Aznar J, et al. Reduced flbfinolytlc octivity in comary heart disease in dasal condition and ajter exercise [ J ]. Thomb Res, 1985, 40: 373-378.
-
9田润华,余云云,申黎艳,葛银林.新诊2型糖尿病患者血清相关炎症因子与HbAlc联检的临床意义[J].放射免疫学杂志,2007,20(5):430-432. 被引量:2
-
10陈良华.降低胆固醇在冠心病防治中的作用[J].国外医学(内科学分册),1997,24(7):291-294. 被引量:33
引证文献3
-
1谢方遒,李伟,管频.PAI-1在糖尿病肾病患者中的变化[J].中国热带医学,2007,7(7):1125-1126. 被引量:2
-
2谢方遒,李伟,管频.2型糖尿病合并高尿酸血症患者纤溶活性研究[J].山东医药,2008,48(4):69-70. 被引量:2
-
3耿明霞,马杰,王望东,吴勇进.2型糖尿病肾微血管病变患者PAI-1、TNF-α水平变化[J].微循环学杂志,2009,19(4):48-49. 被引量:1
二级引证文献5
-
1孟冲,任耘.辛伐他汀治疗糖尿病肾病非降脂作用机制研究进展[J].天津药学,2012,24(6):36-39. 被引量:2
-
2韩业宏,许筠.血浆tPA和PAI-1与糖尿病肾病的关系[J].广东医学,2013,34(10):1631-1632. 被引量:4
-
3张培培,李中南.萆苓方对糖尿病痛风模型大鼠PAI-1的影响[J].江西中医学院学报,2012,24(6):73-76.
-
4卢鹏,吴玉梅.中药治疗糖尿病肾病分子机制研究进展[J].山东医药,2014,54(46):98-100. 被引量:5
-
5杨志新,刘燕凤,曹翼,杨超茅,徐欢.三黄祛瘀汤联合西药治疗2型糖尿病气阴两虚、脉络瘀阻证的临床疗效及对患者血尿酸水平和颈动脉内中膜厚度的影响[J].河北中医,2020,42(6):882-887. 被引量:6
-
1马建林,林劲,苏哲坦,王圣,吴明,李斌,王卫,陈关良.冠心病心绞痛患者体内纤溶系统的变化及其临床意义[J].岭南心血管病杂志,2011,17(S1):70-70.
-
2马建林,林劲,苏哲坦,李斌,王卫,陈关良.冠心病心绞痛患者体内纤溶系统的变化及临床意义[J].中国医药,2011,6(1):3-4. 被引量:7
-
3马虹,王方正.组织型纤溶酶原激活剂治疗急性心肌梗塞与心室晚电位观察[J].中华内科杂志,1990,29(5):274-276.
-
4吕高友,张沈洁,郭凤红,李曦光.纤溶酶原激活物抑制剂-1与糖尿病足发病关系的研究[J].蚌埠医学院学报,2011,36(6):577-578.
-
5梅宇,富路.纤溶酶原激活物抑制剂-1与动脉粥样硬化[J].中国实用内科杂志,2001,21(1):48-50. 被引量:13
-
6汤涌,刘远厚.缬沙坦和苯那普利对慢性充血性心力衰竭患者纤溶系统影响的研究(摘要)[J].泸州医学院学报,2001,24(5):454-454.
-
7郭丽萍,王保法.成人呼吸窘迫综合征与纤溶系统[J].内科急危重症杂志,1997,3(3):122-123.
-
8崔宁.Lp(a)与纤溶系统[J].医学新知,1996,6(1):39-42.
-
9张绪洪,程彦华,邵建华.急性心肌梗死患者纤溶活性的变化[J].岭南心血管病杂志,2000,6(3):204-204. 被引量:1
-
10徐琳,崔志澄.纤溶系统与冠心病[J].北京医学,1996,18(1):36-38. 被引量:1